OrganiGram Stock Forecast, Price & News

OrganiGram (NASDAQ:OGI) Frequently Asked Questions

Is OrganiGram a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OrganiGram stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGI, but not buy additional shares or sell existing shares.
View analyst ratings for OrganiGram or view top-rated stocks.

What stocks does MarketBeat like better than OrganiGram?

Wall Street analysts have given OrganiGram a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OrganiGram wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is OrganiGram's next earnings date?

OrganiGram is scheduled to release its next quarterly earnings announcement on Monday, November 29th 2021.
View our earnings forecast for OrganiGram.

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) released its quarterly earnings data on Monday, July, 12th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The company earned $16.55 million during the quarter, compared to analyst estimates of $13.95 million. OrganiGram had a negative net margin of 190.24% and a negative trailing twelve-month return on equity of 19.91%.
View OrganiGram's earnings history.

How has OrganiGram's stock price been impacted by COVID-19 (Coronavirus)?

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OGI shares have increased by 39.0% and is now trading at $2.39.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for OGI?

8 analysts have issued twelve-month price targets for OrganiGram's stock. Their forecasts range from $3.50 to $6.00. On average, they anticipate OrganiGram's share price to reach $4.21 in the next year. This suggests a possible upside of 76.3% from the stock's current price.
View analysts' price targets for OrganiGram or view top-rated stocks among Wall Street analysts.

Who are OrganiGram's key executives?

OrganiGram's management team includes the following people:

• Beena G. Goldenberg, Chief Executive Officer
• Derrick W. West, Chief Financial Officer
• Paolo de Luca, Chief Strategy Officer
• Borna Zlamalik, Vice President-Innovation
• Tim Emberg, Senior VP-Sales & Commercial Operations

Who are some of OrganiGram's key competitors?

Some companies that are related to OrganiGram include Emergent BioSolutions (EBS), ACADIA Pharmaceuticals (ACAD), Zentalis Pharmaceuticals (ZNTL), Amicus Therapeutics (FOLD), Agios Pharmaceuticals (AGIO), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), Sage Therapeutics (SAGE), Atea Pharmaceuticals (AVIR), Arcus Biosciences (RCUS), Cassava Sciences (SAVA), Pacira BioSciences (PCRX), OPKO Health (OPK), Taro Pharmaceutical Industries (TARO) and Erasca (ERAS).
View all of OGI's competitors.

What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), The Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), Cannabics Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Who are OrganiGram's major shareholders?

OrganiGram's stock is owned by a variety of retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (0.00%), Penserra Capital Management LLC (0.30%), Morgan Stanley (0.29%), Morgan Stanley (0.28%), Bank of Montreal Can (0.27%) and Millennium Management LLC (0.21%).

Which institutional investors are selling OrganiGram stock?

OGI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, CIBC World Markets Inc., Penserra Capital Management LLC, Squarepoint Ops LLC, Renaissance Technologies LLC, IMC Chicago LLC, Goldman Sachs Group Inc., and Bank of America Corp DE.

Which institutional investors are buying OrganiGram stock?

OGI stock was acquired by a variety of institutional investors in the last quarter, including Jump Financial LLC, Deutsche Bank AG, Morgan Stanley, Morgan Stanley, Bank of Montreal Can, Group One Trading L.P., BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, and Susquehanna International Group LLP.

How do I buy shares of OrganiGram?

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $2.39.

How much money does OrganiGram make?

OrganiGram has a market capitalization of $716.56 million and generates $64.61 million in revenue each year. The company earns $-101,290,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does OrganiGram have?

OrganiGram employs 517 workers across the globe.

What is OrganiGram's official website?

The official website for OrganiGram is www.organigram.ca.

Where are OrganiGram's headquarters?

OrganiGram is headquartered at 35 English Dr., Moncton Z4, E1E 3X3.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at (844) 644-4726.